공지 • Feb 21
NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.2 million. NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.2 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 133,333,333
Price\Range: AUD 0.0015
Transaction Features: Subsequent Direct Listing 공지 • Feb 18
NeuRizer Ltd. has filed a Follow-on Equity Offering in the amount of AUD 0.2 million. NeuRizer Ltd. has filed a Follow-on Equity Offering in the amount of AUD 0.2 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 133,333,333
Price\Range: AUD 0.0015
Transaction Features: Subsequent Direct Listing 공지 • Feb 08
NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.3068 million. NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.3068 million.
Security Name: Oridnary Shares
Security Type: Common Stock
Securities Offered: 159,800,000
Price\Range: AUD 0.001
Security Name: Oridnary Shares
Security Type: Common Stock
Securities Offered: 147,000,000
Price\Range: AUD 0.001
Transaction Features: Subsequent Direct Listing Board Change • Feb 04
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Non-Executive Director Manyoo Han was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. 공지 • Jan 22
NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.15 million. NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.15 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 100,000,000
Price\Range: AUD 0.0015
Transaction Features: Subsequent Direct Listing Board Change • Dec 24
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Non-Executive Director Manyoo Han was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. 공지 • Dec 11
NeuRizer Ltd. has filed a Follow-on Equity Offering in the amount of AUD 0.3068 million. NeuRizer Ltd. has filed a Follow-on Equity Offering in the amount of AUD 0.3068 million.
Security Name: Oridnary Shares
Security Type: Common Stock
Securities Offered: 306,800,000
Price\Range: AUD 0.001
Transaction Features: Subsequent Direct Listing 공지 • Oct 30
NeuRizer Ltd., Annual General Meeting, Nov 28, 2024 NeuRizer Ltd., Annual General Meeting, Nov 28, 2024. New Risk • Jul 17
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: AU$14.3m (US$9.62m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$13m free cash flow). Share price has been highly volatile over the past 3 months (54% average weekly change). Earnings have declined by 17% per year over the past 5 years. Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (AU$14.3m market cap, or US$9.62m). New Risk • May 26
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 60% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$13m free cash flow). Share price has been highly volatile over the past 3 months (42% average weekly change). Earnings have declined by 17% per year over the past 5 years. Shareholders have been substantially diluted in the past year (60% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (AU$3.80m market cap, or US$2.52m). Board Change • Apr 15
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Company Secretary & Non-Executive Director Jordan Mehrtens was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. 공지 • Feb 12
NeuRizer Ltd. Appoints Jordan Mehrtens as Non-Executive Director NeuRizer Ltd. announce that Ms Jordan Mehrtens has been appointed as a non-executive Director of the Company, effective 11 February 2024. Ms Mehrtens is the Company Secretary and has been for the past 9 years, with the key terms of her employment agreement detailed below. Ms Mehrtens is a qualified Lawyer and has a Bachelor of Commerce (Finance) and a Graduate Diploma in Urban and Regional Planning. Ms Mehrtens has worked with the NeuRizer Urea Project since its commencement, providing regulatory, compliance and other analytical advice. Ms Mehrtens is a member of the Governance Institute of Australia (GIA) and holds a Certificate in Governance Practice from the GIA. New Risk • Jan 18
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 21% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 25% per year over the past 5 years. Earnings have declined by 25% per year over the past 5 years. Revenue is less than US$1m. Revenue is less than US$1m. Market cap is less than US$10m (AU$9.65m market cap, or US$6.34m). Minor Risks Shareholders have been diluted in the past year (24% increase in shares outstanding). Shareholders have been diluted in the past year (24% increase in shares outstanding). 공지 • Jan 16
Neurizer Ltd. Announces Executive Changes NeuRizer Ltd. announced that as a result of a corporate review the position of Managing Director has been made redundant. The Executive Chairman will assume the duties previously undertaken by the Managing Director. Assuch Phil Staveley will cease being the Managing Director of NRZ on the 15th of January 2024. 공지 • Dec 20
NeuRizer Ltd. Announces Step Down of Murray Chatfield from the Board NeuRizer Ltd. advised that after more than 7 years as non-executive director, Mr. Murray Chatfield has decided to step down from the NeuRizer Board effective immediately. Murray joined the board in 2015 as an independent director. In that time he has provided valuable input and guidance to the Company. His endless energy, vast knowledge of financial markets and products combined with a passion for relevant targeted innovation has been a valuable and deep resource for NeuRizer. Murray attended every board and audit committee meeting over his 7 years and has always worked to ensure that the best interests of shareholders were at the forefront in the decision making of the Company. New Risk • Nov 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 25% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (AU$34.5m market cap, or US$21.9m). 공지 • Oct 11
NeuRizer Ltd., Annual General Meeting, Nov 10, 2023 NeuRizer Ltd., Annual General Meeting, Nov 10, 2023, at 09:30 Cen. Australia Standard Time. Agenda: To consider the financial report and the reports of the Directors and of the Auditors for the financial year ended 30 June 2023; to consider adoption of the Remuneration Report for the year ended 30 June 2023; to consider re-election of Directors of the Company; to consider approval to issue Placement Shares; to consider ratification of the issue of shares for March and September Placement Shares; to consider ratification of the issue of options to March Broker Options; to consider Issue of Options to Zhe Wang, Zheng Xiaojiang and Murray Chatfield in lieu of pay; and to consider approval of additional 10% Placement Capacity. New Risk • Oct 02
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 28% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (AU$47.0m market cap, or US$30.2m). 공지 • Sep 06
NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 1 million. NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 1 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 20,000,000
Price\Range: AUD 0.05
Transaction Features: Subsequent Direct Listing 공지 • Aug 01
NeuRizer Ltd. Announces Change of Directors NeuRizer Ltd. announced that Mr. Sunghun Ryu has been appointed as a Non-Executive Director of the Company, effective 31 July 2023. This follows the resignation of Mr. Jaehyung Yoo from the Board of NRZ. Mr. Yoo joined the NRZ Board in August 2022 and has resigned due to a change in Mr. Yoo's role at DL E&C Co. Ltd. (DL E&C). Mr. Ryu is the Vice President of Strategy & Planning, Plant Business Division of DL E&C. Recent Insider Transactions • Jun 09
MD & Director recently sold AU$194k worth of stock On the 1st of June, Phillip Staveley sold around 2m shares on-market at roughly AU$0.097 per share. This transaction amounted to 25% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Phillip's only on-market trade for the last 12 months. 공지 • May 10
NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 1 million. NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 1 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 14,285,714
Price\Range: AUD 0.07
Transaction Features: Subsequent Direct Listing Board Change • Mar 01
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Non-Executive Independent Director Wang Zhe was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.